Company Overview
Wellgistics Health, Inc. operates within the healthcare sector as a pharmaceutical retailer, specifically engaging in the wholesale and distribution of pharmaceutical products to manufacturers and independent retail pharmacies across the United States. The company's portfolio includes the distribution of branded and generic pharmaceuticals, alongside over-the-counter healthcare and consumer products, positioning it as a critical supply chain partner for the medical industry. As of the latest data, the company maintains a market capitalization of $10.59M and generates annual revenue of $23.34M, while the number of employees is not disclosed in available records. These valuation and revenue figures indicate a small-cap enterprise with a relatively modest financial footprint compared to large-scale national distributors, suggesting a niche operational scope rather than broad market dominance. The price-to-sales ratio of 0.45 further contextualizes the company's scale, implying that the market values the firm at less than half of its annual sales generation, which is characteristic of specialized wholesale operations facing significant margin compression.
Financial Health
The company reported a trailing twelve-month revenue of $23.34M, yet this generated a net income of -$101,274,528, revealing a severe structural disconnect where operating costs and expenses vastly exceed gross revenue. This massive disparity between revenue and net income highlights an extremely fragile cost structure where the business is burning through capital at a rate that cannot be sustained by current sales levels. Despite the negative net income, the entity generated positive free cash flow of $7.64M, which provides a limited degree of financial flexibility by offering liquidity to cover essential operational obligations without immediate external financing. However, the company's gross margin stands at -27.5%, indicating that the cost of goods sold is exceeding total revenue, a fundamental breakdown in the core revenue-generating model. The operating margin is even more distressed at -766.0%, and the profit margin is recorded at 0.0%, collectively signaling that the company is not profitable at any level of its current operations. On the balance sheet, the company holds only $42,571 in cash against total debt of $24.58M, creating a precarious liquidity position where liabilities significantly outweigh liquid assets. Furthermore, the debt-to-equity ratio is not available, but the presence of negative price-to-book and return on assets suggests capital erosion. The current ratio is 0.10, which explicitly indicates a severe inability to meet short-term liabilities with short-term assets, flagging immediate liquidity risk. Return on equity is not available due to the equity deficit, while the return on assets is -115.6%, demonstrating that the management team has been ineffective at generating value from the assets employed in the business.
Valuation Assessment
The P/E ratio (TTM) is not available, and the forward P/E is also not available, meaning traditional earnings-based valuation models cannot be applied to assess the company's expected earnings trajectory or future profitability. The price-to-book ratio is -0.82, a negative figure that indicates the market is valuing the company below the book value of its assets, often reflecting investor skepticism regarding the recoverability of assets given the operational losses. The price-to-sales ratio of 0.45 and the EV/EBITDA of -0.45 serve as alternative metrics that suggest the market is pricing in significant distress, as the negative EV/EBITDA confirms that earnings before interest, taxes, depreciation, and amortization are currently negative. The stock has experienced extreme volatility, trading between a 52-week low of $0.10 and a 52-week high of $7.04, illustrating a wide trading range driven by the company's fundamental instability. Without a beta value available, the specific volatility relative to the broader market cannot be quantified, but the wide spread between the high and low implies significant price sensitivity to market sentiment. The absence of a standard P/E and forward P/E suggests that analysts are likely relying on asset-based or liquidation values rather than earnings multiples to gauge fair value.
Growth & Income
The company recorded a revenue growth rate of -86.5% year-over-year, while earnings growth is not available due to the persistent negative net income, indicating a severe contraction in business volume rather than organic expansion. The inability to generate positive earnings growth while revenue declines sharply implies that the company is losing market share or facing unsustainable demand conditions within the pharmaceutical distribution sector. Wellgistics Health, Inc. does not pay dividends, evidenced by a dividend yield that is not available and a payout ratio of 0.0%, which means the company retains all of its minimal earnings, if any, but currently retains nothing as it is unprofitable. The 0.0% payout ratio technically reflects a lack of distributable income rather than a strategic choice to reinvest, as the company must use its scarce cash reserves to maintain operations. Consequently, the overall growth and income profile is characterized by rapid revenue contraction and a complete absence of cash distributions to shareholders, presenting a high-risk scenario for income-oriented investors.